Formulation-driven oncology—built to unlock combination
With 20+ years at the intersection of materials science (nano/hydrogel-based particles) and immunology, Dr. Kim focuses on translating platform science into clear development paths—from formulation design to clinical readiness. ANGel is the result of accumulated platform know-how, patient-driven needs, and execution-focused team building.
Key Facts
- 20+ years in nano/hydrogel-based particles and immunology R&D
- Ph.D. in Chemistry, Georgia Institute of Technology (Georgia Tech) / Best Doctoral Thesis Award
- Research Fellow, Harvard Medical School (Springer’s Lab)
- 40+ peer-reviewed publications (Nature, PNAS, Nat. Communications, JACS, and more)
- Cumulative Journal Impact Factor (sum): 367+
- Proven commercialization track record via tech transfer of a coagulation factor diagnostic technology
The core strength is not just discovery—it’s structuring science into a platform that can move through staged validation. The approach centers on engineering what drives outcomes in combination therapy: exposure, persistence, and controllable co-delivery, then expanding through fast, partner-enabled proof generation.
-
Scientific Depth
Two decades of work across nano/hydrogel particle engineering and immunology, building the conceptual and technical foundation behind precision formulation and delivery.
-
Translation & Commercialization
Demonstrated end-to-end leadership from early-stage R&D through productization, including successful technology transfer and commercialization experience.
-
Global Network
A global academic and industry network built through Harvard Medical School experience—supporting strategic pathways into the US and Europe.
-
Execution
Platformization, strategic pivots, and clinical preparation—driven with speed and precision. Focused on making “the next step” operational for the team and partners.
-
Credentials
-
Ph.D., Chemistry — Georgia Institute of Technology (Georgia Tech) / Best Doctoral Thesis Award
-
Research Fellow — Harvard Medical School, Springer’s Lab
-
Publications: 40+ peer-reviewed papers (Nature, PNAS, Nat. Communications, JACS, etc.)
-
Cumulative Journal Impact Factor (sum): 367+
The goal is to set a new bar for immuno-oncology—one that includes not only what you use, but how you deliver it to make it work. Built around precision formulation and delivery, the strategy is to validate faster, scale smarter, and expand through collaboration.